RAPGEF3 and neoplasm: We notice that either EGFR TKI or RAPGEF3 inhibitor alone has marginal inhibitory effect on tumor growth, whereas the antitumor effect is dramatically enhanced upon combinational therapy in RAPGEF3high tumors.